Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 3/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.33 |
| ▸ | ESRRA | P11474 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072310 | 0.93 | HSD17B10 (0.37) | HSD17B10PTPN1MRGPRX1ESRRAPTPN2 | |
| SCHEMBL6072284 | 0.90 | IDO1 (0.33) | ACLYIDO1KDM4EALDH1A1 | |
| SCHEMBL6072762 | 0.89 | IDO1 (0.32) | ACLYPTPN1IDO1KDM4EALDH1A1 | |
| SCHEMBL6071815 | 0.89 | SMN1; SMN2 (0.34) | IDO1ALDH1A1 | |
| SCHEMBL6072322 | 0.88 | PDE10A (0.32) | IDO1 | |
| SCHEMBL6072777 | 0.88 | AKR1C3 (0.35) | ACLYIDO1KDM4EALDH1A1 | |
| SCHEMBL6072447 | 0.87 | IDO1 (0.33) | IDO1 | |
| SCHEMBL6072191 | 0.87 | ACLY (0.38) | ACLYIDO1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL6072006 | 0.86 | SSTR5 (0.32) | HSD17B10KDM4EALDH1A1 | |
| SCHEMBL6072317 | 0.86 | IDO1 (0.31) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | HSD17B10 102/4885ACLY 1588/4885PTPN1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.